Beneficial Effect of Luteal-phase Gonadotropin-releasing Hormone Agonist Administration on Implantation Rate Afterintracytoplasmic Sperm Injection
Objective: To evaluate the effect of gonadotropin-releasing hormone (GnRH) agonist, administered in the luteal phase, on intracytoplasmic sperm injection (ICSI) outcome. Materials and Methods: One hundred and eighty women undergoing ovarian stimulation for ICSI were enrolled in this study. Patients...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2009-09-01
|
| Series: | Taiwanese Journal of Obstetrics & Gynecology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1028455909602977 |
| Summary: | Objective: To evaluate the effect of gonadotropin-releasing hormone (GnRH) agonist, administered in the luteal phase, on intracytoplasmic sperm injection (ICSI) outcome.
Materials and Methods: One hundred and eighty women undergoing ovarian stimulation for ICSI were enrolled in this study. Patients were randomly assigned to receive a single dose of GnRH agonist or placebo. Implantation rate and clinical pregnancy rate were the main outcomes.
Results: Administration of 0.1 mg of the GnRH agonist triptorelin on day 3 after embryo transfer led to a significant improvement in implantation rate (12.3% vs. 7.3%) and clinical pregnancy rate (25.5% vs. 10.0%) as compared with placebo.
Conclusion: Luteal phase GnRH agonist administration enhances ICSI clinical outcomes. |
|---|---|
| ISSN: | 1028-4559 |